Comparative Pharmacology
Head-to-head clinical analysis: PFIZERPEN A versus PFIZERPEN AS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PFIZERPEN A versus PFIZERPEN AS.
PFIZERPEN-A vs PFIZERPEN-AS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Penicillin G inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidase activity and activating autolytic enzymes.
PFIZERPEN-AS (penicillin G procaine) inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidation and transglycosylation, leading to cell lysis.
1-2 million units intramuscularly or intravenously every 4 hours; or continuous intravenous infusion of 20-30 million units per day.
250-500 mg orally every 6-8 hours for moderate infections; 500 mg to 2 g intravenously every 4-6 hours for severe infections.
None Documented
None Documented
Terminal elimination half-life: 0.6-0.8 hours in adults with normal renal function; prolonged to 7-10 hours in end-stage renal disease (ESRD). In neonates, half-life ranges 2-4 hours.
0.5-1 hour in healthy adults; prolonged to 2.5-10 hours in renal impairment (CrCl <10 mL/min). Clinically relevant for dosing interval adjustment in renal dysfunction.
Primarily renal (60-70% unchanged via glomerular filtration and tubular secretion); hepatic metabolism minor (<10%); biliary/fecal elimination <10%.
Primarily renal (60-80% as unchanged drug via tubular secretion and glomerular filtration); minor biliary/fecal elimination (10-20%)
Category C
Category C
Antibiotic (Penicillin)
Antibiotic (Penicillin)